key: cord-0946076-v762xh5e
authors: Zhang, Rui; Ni, Leng; Di, Xiao; Wang, Xuebin; Ma, Baitao; Niu, Shuai; Liu, Changwei
title: Prevalence of Venous Thromboembolic Events in COVID-19 Patients: Systematic Review and Meta-analysis
date: 2020-12-09
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2020.11.023
sha: b2f286490b48f06bf6ed46ad42c5b354f4cfeed0
doc_id: 946076
cord_uid: v762xh5e

BACKGROUND: Emerging clinical evidence has shown that COVID-19 patients are complicated with venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE). The prevalence of VTE in hospitalized COVID-19 patients is unclear. METHODS: Eligible studies on COVID-19 were collected from PubMed, Web of Science, and Embase. Patient characteristics and information were extracted for three categories of patients: Consecutive, ICU, and non-ICU group. All PEs and DVTs were diagnosed by computed tomographic pulmonary arteriography and duplex ultrasound, respectively. A subgroup analysis of testing strategies in ICU and non-ICU patients for PE and DVT was also performed. RESULTS: Forty clinical studies involving 7966 hospitalized COVID-19 patients were included. Pooled VTE prevalence was 13% in consecutive patients (95%CI: 0.05–0.24; I(2)=97%), 7% in non-ICU patients (95%CI: 0.01-0.18; I(2)=93%), and 31% in ICU patients (95%CI: 0.22–0.42; I(2)=91%). ICU patients had the highest prevalence of PE among the three groups (17%, 95%CI: 0.12-0.23, vs. 8% in consecutive patients with 95%CI: 0.04-0.13, 4% in non-ICU with 95%CI: 0.01-0.08). ICU patients also had the highest DVT prevalence (25%, 95%CI: 0.14-0.37, vs. 7% in consecutive patients with 95%CI: 0.03-0.14, 7% in non-ICU with 95%CI: 0.02-0.14). The subgroup analysis showed a 3-fold improvement in PE and DVT detections rate in both ICU and non-ICU patients with COVID-19 when screening test for VTE was applied. In the settings of screening tests for VTE, ICU patients have a significantly higher prevalence of PE (37% vs. 10%, p<0.0001) and DVT (40% vs. 12%, p=0.0065) compared to non-ICU patients. CONCLUSIONS: VTE is common in hospitalized COVID-19 patients, especially among ICU patients. Screening tests for PE and DVT may significantly improve detection rates in both ICU and non-ICU patients with COVID-19 than tests based on clinical suspicion.

cases were also excluded. In selecting literature, ZR and XD would independently assess the 14 qualification of studies according to exclusion and inclusion criteria. LN will independently 15 decide whether to include or exclude a study if there is discordance. 16 17 Data extraction 18 Information regarding author, study location, study design, demographics, and the sample size 7 patients. DVT, PE, and VTE events were obtained from the included studies. If the study did not 1 report the number of VTE events, we added DVT and PE events together as the number of VTE 2 events. Information on whether VTE was diagnosed by screening or testing based on clinical 3 suspicion was also collected for each patient. The Joanna Briggs Institute's critical appraisal checklist tool for a prevalence study was 16 employed for quality assessment of the included studies [8] . The checklist includes nine 17 questions with four categories of answers: yes, no, unclear, and not applicable for insufficient 18 data. "Yes" is scored as 1, and "no" is scored as 0, with a total quality score ranging from 0-9.

Quality assessment was carried out by independent reviewers (LN and XD). We employed the "meta" (version 4.12-0) and "forrestplot" (version 1.9) packages in R 2 (version 3.6.2) to perform the meta-analysis. The Shapiro-Wilk test was introduced as a 3 normality test, and log transformation was used. Prevalence with a 95% confidence interval 4 (95%CI) was used. A random-effects model was developed for significant heterogeneity (p<0.10 5 or I 2 >50%), and a fixed-effects model was used for non-significant heterogeneity (p>0.10 or 6 I 2 <50%). A funnel plot and the Egger test were employed for assessment of publication bias. A 7 two-sided p<0.05 was regarded as statistically significant. Pooled results for the prevalence of 8 VTE, PE, and DVT in each group were analyzed, and a subgroup analysis of screening or testing 9 upon indication of symptoms for VTE, PE, and DVT was conducted. 

Study selection and summary of studies 13 Systematic searches obtained a total of 2005 citations. After excluding duplicates and applying 14 the inclusion/exclusion criteria, forty-one articles remained and met the inclusion criteria for 15 quality appraisal after the full-text examination ( Figure 1 ) [4, . In the quality assessment, 16 thirty-one articles received a score of 8 out of 9, and nine studies received a score of 9 out of 9. 17 18 Thirty-four retrospective studies and six prospective studies were included in this 9 the included patients. Regarding comorbidities, 46.1% (1191 Regarding comorbidities, 46.1% ( /2582 ICU patients, and non-ICU patients [12, 14, 17, 18] . In total, 16 studies underwent screening tests 10 for VTE. There were six studies in which patients were routinely screened for DVT by DUS 11 while CTPA was performed only for suspected PE. Another 17 studies use imaging tests only for 12 symptomatic or suspected VTEs. One study did not report a screening test strategy for VTE.

Outcome of meta-analysis 15 All meta-analyses were performed by random-effects models. The pooled prevalence of VTE, 16 PE and DVT for consecutive hospitalized patients were 13% (95%CI: 0.05-0.24), 8% (95%CI: 17 0.04-0.13), and 7% (95%CI: 0.03-0.14), respectively. ICU patients had a pooled VTE 18 prevalence of 31% (95%CI: 0.22-0.42), which was significantly higher than non-ICU patients 19 (prevalence 7%; 95%CI: 0.01-0.18, p=0.0012). Compared to non-ICU patients, ICU patients 20 also had three-fold higher pooled prevalence of PE (17%, 95%CI: 0.12-0.23 vs. 4%, 95%CI: 21 J o u r n a l P r e -p r o o f 10 0.01-0.08, p=0.0001) and DVT (25%, 95%CI: 0.14-0.37 vs. 7%, 95%CI: 0.02-0.14, p=0.0043) 1 ( Figure 2 ). In the subgroup analysis, the prevalence of PE and DVT obtained from screening or testing on 4 clinical suspicion was compared. For ICU patients, the PE prevalence for screening (prevalence 5 37%, 95%CI: 0.30-0.44) was significantly higher than that for testing on clinical suspicion 6 (prevalence 12%, 95%CI: 0.08-0.16) (p<0.0001). Screening for DVT in ICU patients also 7 significantly improved the detection rate compared with testing on clinical suspicion (40% vs. 8 11%, p=0.0069). Similarly, consecutive patients with COVID-19 showed significant difference 9 in detection rate by two testing strategies for the diagnosis of PE (22% vs. 5%, p<0.0001) and 10 DVT (33% vs. 2%, p=0.0010). As for non-ICU patients, DVT screening test increased the 11 detection rate (12% vs. 1%, p=0.0007). However, the difference in the detection of PE by 12 different test strategies in non-ICU patients did not reach significance (10% vs. 3%, p=0.0530).

Despite testing strategies, ICU patients had a significantly higher prevalence of PE and DVT 14 than non-ICU patients ( Figure 3 ).

The results of the funnel plot and Egger's test showed a potential publication bias in the 17 prevalence of VTE and PE in ICU patients. No potential publication bias of VTE, PE, and DVT 18 was reported in consecutive patients and non-ICU patients (Supplemental material Figure 1 -3).

There was no potential publication bias reported in the Egger's test of PE and DVT prevalence in 1 both ICU and non-ICU patients (Supplemental material Figure 4 ). The present study demonstrated a significantly higher prevalence of VTE, PE, and DVT in ICU 9 patients with COVID-19 compared with non-ICU patient group, which is consistent with 10 previous studies. In this study, the pooled PE prevalence of ICU patients was 17%. Similarly,

Poissy et al.

[42] reported a notably higher PE prevalence in ICU patients with COVID-19 12 compared with other ICU patients and ICU patients with influenza. In their center, the PE 13 prevalence was 20.6% in ICU patients with COVID-19 (22/107), compared with 6.1% in other 14 ICU patients (12/196) and 7.5% in ICU patients with influenza (7.5%) during the same period.

Similarly, there was a significant difference in the DVT prevalence between ICU and non-ICU 16 patients in this study, which is in line with previous reports [49] . 17 18 Although unclear, the discrepancy between the PE and DVT prevalence in ICU patients with patients. Considering the more severe condition, higher mortality rate, and a higher prevalence of 5 VTE in ICU patients, screening for VTEs may be acceptable for ICU patients. Still, whether 6 screening test for VTE in COVID-19 patients necessary is worthy of further study. therapeutic anticoagulation, which may influence the VTE's prevalence. Finally, included studies 14 that were retrospective in nature were also inherently limited. Therefore, the results were limited 15 by low-quality evidence due to heterogeneity and potential risk of bias. A prospective study with 16 a larger sample size and justified measurement strategies is warranted. For more information, visit: www.prisma-statement.org.

Page 2 Table 1 . Summary of forty studies for meta-analysis.

14

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram

For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations

Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12)

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot

Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency

Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15)

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers)

Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias)

Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research

CORRESPONDING AUTHOR RESPONSIBILITY. The corresponding author confirms that they and the co-authors have read and agreed to follow the policies of the Journal of Vascular Surgery Publications. The corresponding author also confirms that they and the co-authors have approved the manuscript files, disclosed all relevant conflicts of interest, and verified their contributions and conflicts on this form prior to submission. The corresponding author is responsible for serving these same functions for the revision and resubmission of this work.

Please include the names of the corresponding author and the post-publication corresponding author on the title page of the manuscript.

Please select one option.☒ COMPLETELY ORIGINAL. The authors certify that this manuscript is original, has been written by the stated authors, has not been published previously, and is not under consideration for publication by another journal.☐ FOLLOW UP. This work is a follow up from a previously published study. It contains a patient cohort that has been reported previously. table to indicate their involvement in the creation of this manuscript. It is important that a box is checked in each authorship category, otherwise the person will not qualify for authorship and the manuscript will be returned to the authors for correction.The boxes for "Approval" and Accountability" must be checked for ALL authors. If an author declines to approve or be accountable for the work, they may not be included as authors.CRITERIA REQUIRED FOR AUTHORSHIP. Authors must have contributed in all four categories. 

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

List 2 initials for each author (example: AS, BP). In the case of two authors with the same initials, please use their middle initial to differentiate between them (example: JEB, JTB). 

You may add more rows if needed.

Overall responsibility. Changwei Liu assumes overall responsibility and guarantees the scientific integrity of the work as a whole.

☐ ☐ ☐ ☐ SHARED FIRST AUTHORSHIP: Check this box if two authors participated equally and should share "first authorship".List these as first and second authors.

If two authors participated equally and should share "senior authorship" enter their initials here:

EACH author must disclose all relevant financial and nonfinancial potential conflicts of interest with respect to this manuscript. Potential conflicts of interest include, but are not limited to:1. A financial contribution to the author or the authors' institution from a company or organization that might benefit (or lose) financially from the results, conclusions or discussion presented in the manuscript Examples include: Royalties, Patents (or patents pending), fees for consulting, fees for speaking when organized by a corporate sponsored speakers' bureau, funds for a member of the author's staff or family 2. Ownership of stocks, shares or options in a company or organization that might benefit (or lose) financially from the results, conclusion or discussion presented in the paper/letter 3. A commercial interest in the form of a relationship with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients 4. Other potential conflicts include: a. an academic association or antagonism with someone whose interest might be affected by the paper b. membership in a special interest group whose interests might be affected by the paper c. other strong convictions that might have affected what was written List conflicts of interest for EACH author below. If there are no conflicts of interest, please state "The authors have no competing interests" in the space below.

J o u r n a l P r e -p r o o f

Each author must disclose the name and involvement of all entities that provided financial support for this work. Please list the funding (grant, scholarships, donated devices, etc.) and describe the involvement of each sponsor in the: 1. Study design; collection, analysis, and interpretation of data; 2. Manuscript writing 3. The decision to submit the manuscript for publication 4. Any other involvement in the creation of the manuscript (Artwork, critical revision, etc.)

The authors must make a meaningful disclosure regarding their discussions of off label or unapproved drugs or devices.☐ This study does include off label drugs and/or devices.The specific names of the products discussed are: Click or tap here to enter text.☒ This study does not include off label drugs and/or devices.The corresponding author confirms that they and the co-authors believe that this form and all accompanying files describe truthful facts. The corresponding author also certifies that they and each co-author have participated to a sufficient degree to take public responsibility for this manuscript, that their contributions and relevant conflicts of interest are accurately and completely reported on this form. 

Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.Page 6-7Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.

Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.

Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).Page 7Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.

Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.Page 7

12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. Page 7Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.Page 7